Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | FPR2 | P25090 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | MYLK | Q15746 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 7/20 | 0.46 |
| ▸ | THPO | P40225 | 4/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8670017 | 0.93 | CYP3A4 (0.51) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL2905720 | 0.87 | MAPK1 (0.42) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL2910432 | 0.85 | CYP3A4 (0.41) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL9193448 | 0.84 | CYP3A4 (0.51) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL2902837 | 0.84 | CYP3A4 (0.38) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL2909360 | 0.83 | CYP3A4 (0.68) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL2910152 | 0.82 | EDNRA (0.39) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL2909004 | 0.82 | CYP3A4 (0.60) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL2927478 | 0.81 | CYP3A4 (0.47) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL2909415 | 0.80 | SLC6A9 (0.39) | CYP3A4CYP1A2CYP2C19CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479386-A1 | Use of isoquinoline-derivatives for treating and preventing pigmentary disorders | Switch Biotech Aktiengesellschaft (DE) | 2004-11-24 | — | — | EP | claimed |
| EP-0956865-B2 | MEDICINES COMPRISING Rho KINASE INHIBITOR | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION | 2009-02-05 | — | — | US | disclosed |
| WO-2008049000-A2 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-0956865-B1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | MITSUBISHI PHARMA CORP (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-6906061-B2 | Pharmaceutical agent containing Rho kinase inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2005-06-14 | — | — | US | disclosed |
| EP-1479386-A1 | Use of isoquinoline-derivatives for treating and preventing pigmentary disorders | Switch Biotech Aktiengesellschaft (DE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2004062666-A2 | USE OF RHO-KINASE INHIBITORRS FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | UNIVERSITY COLLEGE LONDON (GB) | 2004-07-29 | — | — | WO | disclosed |
| US-20030134775-A1 | Pharmaceutical agent containing Rho kinase inhibitor | UEHATA MASAYOSHI (JP) | 2003-07-17 | — | — | US | disclosed |
| US-6451825-B1 | FOR THERAPY OF HYPERTENSION, A THERAPEUTIC AGENT OF ANGINA PECTORIS, A SUPPRESSIVE AGENT OF CEREBROVASCULAR CONTRACTION, ASTHMA, PERIPHERAL CIRCULATION DISORDER, AS PROPHYLACTIC AGENT OF IMMATURE BIRTH, A THERAPEUTIC AGENT OF ARTERIOSCLEROSIS | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
| US-5747507-A | MYOCARDIAL DISEASE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1998-05-05 | — | — | US | disclosed |
| EP-0654266-A1 | CARDIAC PROTECTIVE | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-05-24 | — | — | EP | disclosed |
| EP-0187371-B1 | SUBSTITUTED ISOQUINOLINESULFONYL COMPOUNDS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1991-06-19 | — | — | EP | disclosed |
| US-4678783-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVES, ARTERIOSCLEROSIS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1987-07-07 | — | — | US | disclosed |
| EP-0187371-A2 | Substituted isoquinolinesulfonyl compounds | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134775-A1 | Pharmaceutical agent containing Rho kinase inhibitor | ROCK1, RHOA, ARHGDIA | CYP3A4 3462/4885CYP1A2 2887/4885CYP2C19 2260/4885 |
| US-20090036465-A1 | COMBINATION THERAPY FOR PULMONARY ARTERIAL HYPERTENSION | ROCK1, ROCK2, RHOA | CYP3A4 4667/4885CYP1A2 3990/4885CYP2C19 3818/4885 |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | ROCK1, RHOA, ARHGDIA | CYP3A4 3462/4885CYP1A2 2887/4885CYP2C19 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.